Guizhou Yibai Pharmaceutical Co Ltd (SHG:600594) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Yibai Pharmaceutical Co Ltd (600594)
Guizhou Yibai Pharmaceutical Co Ltd (SHG:600594) has a market capitalization of $403.28 Million (CN¥2.76 Billion) as of September 16, 2026. Listed on the SHG stock exchange, this China-based company holds position #13413 globally and #3981 in its home market, demonstrating a -6.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Yibai Pharmaceutical Co Ltd's stock price CN¥3.48 by its total outstanding shares 791927400 (791.93 Million). Also see Guizhou Yibai Pharmaceutical Co Ltd assets under control for a full breakdown of the balance sheet.
Guizhou Yibai Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Yibai Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.16 Billion to $403.28 Million (-13.21% CAGR). Also see 600594 operating cash flow for how efficiently the company converts equity into cash flow.
Guizhou Yibai Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Guizhou Yibai Pharmaceutical Co Ltd (600594) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.25x
Guizhou Yibai Pharmaceutical Co Ltd's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.70 Billion | $3.69 Billion | $384.86 Million | 0.46x | 4.42x |
| 2017 | $1.05 Billion | $3.81 Billion | $387.53 Million | 0.28x | 2.70x |
| 2018 | $569.08 Million | $3.88 Billion | -$725.50 Million | 0.15x | N/A |
| 2019 | $513.41 Million | $3.36 Billion | $141.90 Million | 0.15x | 3.62x |
| 2020 | $591.63 Million | $3.41 Billion | $228.76 Million | 0.17x | 2.59x |
| 2021 | $942.14 Million | $3.35 Billion | $243.77 Million | 0.28x | 3.86x |
| 2022 | $640.84 Million | $2.74 Billion | -$426.39 Million | 0.23x | N/A |
| 2023 | $659.38 Million | $2.82 Billion | $103.40 Million | 0.23x | 6.38x |
| 2024 | $412.55 Million | $2.17 Billion | -$317.22 Million | 0.19x | N/A |
| 2025 | $461.22 Million | $1.86 Billion | -$329.56 Million | 0.25x | N/A |
Competitor Companies of 600594 by Market Capitalization
Companies near Guizhou Yibai Pharmaceutical Co Ltd in the global market cap rankings as of September 16, 2026. Review 600594 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guizhou Yibai Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Guizhou Yibai Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Yibai Pharmaceutical Co Ltd's market cap moved from $2.16 Billion to $ 403.28 Million, with a yearly change of -13.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥403.28 Million | -12.56% |
| 2025 | CN¥461.22 Million | +11.80% |
| 2024 | CN¥412.55 Million | -37.43% |
| 2023 | CN¥659.38 Million | +2.89% |
| 2022 | CN¥640.84 Million | -31.98% |
| 2021 | CN¥942.14 Million | +59.24% |
| 2020 | CN¥591.63 Million | +15.24% |
| 2019 | CN¥513.41 Million | -9.78% |
| 2018 | CN¥569.08 Million | -45.69% |
| 2017 | CN¥1.05 Billion | -38.35% |
| 2016 | CN¥1.70 Billion | -21.37% |
| 2015 | CN¥2.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Guizhou Yibai Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $403.28 Million USD |
| MoneyControl | $403.28 Million USD |
| MarketWatch | $403.28 Million USD |
| marketcap.company | $403.28 Million USD |
| Reuters | $403.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respirato… Read more